Introduction
Imatinib, an inhibitor of BCR-ABL kinase activity, has been the standard first-line agent to treat chronic myeloid leukemia in chronic phase (CML-CP) for almost 10 years. The efficacy and safety of imatinib were demonstrated in the pivotal IRIS (International Randomized Study of Interferon and STI571) trial in which 1106 patients with CML-CP were randomized to receive imatinib or interferon-a (IFN) plus cytarabine, the previous standard of care, as first-line therapy. The estimated cumulative rate of complete cytogenetic response (CCyR; no Ph þ metaphases in 20/20 cells) in patients receiving imatinib was 69% at 12 months and 87% at 5 years. 1 After 6 years, 63% of patients randomized to imatinib were in CCyR and remained on study. 2 In a subset of patients from three countries (Germany, Australia and New Zealand; n ¼ 98) who underwent regular molecular assessment, rates of major molecular response (MMR, defined as a 3-log reduction in copy number of BCR-ABL transcripts ¼ 0.1% ratio compared with a standardized baseline) increased from 39% at 12 months to 65% at 5 years. 3 As molecular assessments in the IRIS trial were not performed in all patients, these data provided the best estimate of MMR responses to imatinib in the total population. Despite these impressive cumulative response rates, 8-year follow-up of the imatinib arm showed that 8% of patients had loss of complete hematologic response, 18% had loss of CCyR, an estimated 8% transformed to accelerated or blast phase (AP/BP) CML, and approximately 6% discontinued treatment or crossed over to the control arm because of adverse events (AEs) or abnormal laboratory values. 2, 4 Notably, annual rates of loss of response or transformation on imatinib were higher during the first 3 years of treatment (3.3-7 .5%) and declined thereafter (0.3-1.7%). 4 Several other studies have reported the results of first-line imatinib treatment. In an intention-to-treat analysis of 204 consecutive patients with newly diagnosed CML treated at the Hammersmith Hospital in London, 77% of patients achieved a CCyR and 34% achieved a MMR after a median follow-up of 38 months. The probability of remaining in major cytogenetic response (0-35% Ph þ metaphases) at 5 years while still receiving imatinib was 63%, while 25% of patients had discontinued imatinib because of unsatisfactory response and/ or toxicity. 5 After 24 months of follow-up in a population-based study from 12 UK hospitals, 49% of assessable patients with newly diagnosed CML-CP had failed or were intolerant of imatinib, including 6 patients who transformed to BP, 19 who failed to achieve/maintain a CCyR and two who were intolerant to imatinib. 6 In the subset of French patients with CML-CP assessed in the UNIC (Unmet Needs In CML) observational study of CML management in Europe, 9/102 patients (9%) treated with first-line imatinib were imatinib resistant and 22/102 (22%) were imatinib intolerant defined as dose interruption/adjustment or treatment discontinuation. 7 These data indicate that, although imatinib is an effective treatment for newly diagnosed patients with CML-CP, there is room for improvement for a subset of patients who are intolerant to imatinib or who have imatinib-resistant disease.
Characteristics of alternative BCR-ABL inhibitors
An understanding of the mechanisms of imatinib resistance led to the development of second-generation inhibitors, including nilotinib, dasatinib and bosutinib (Table 1) . [8] [9] [10] [11] [12] [13] [14] Like imatinib, nilotinib binds an inactive conformation of BCR-ABL; however, because of an improved topographical fit, binding affinity is increased for ABL kinase but reduced in relative terms for other shared kinase targets, such as platelet-derived growth factor receptor. Compared with imatinib, nilotinib is 10-50-fold more potent in inhibiting proliferation of BCR-ABL-expressing cell lines.
11 Dasatinib binds to a distinct although overlapping binding site within the ATP-binding pocket that requires fewer critical binding residues compared with imatinib. Dasatinib may bind multiple kinase conformations and is 325-fold more potent than imatinib in cell proliferation assays. 8, 15 Bosutinib, which has not yet been approved by regulatory authorities, binds to a conformation of ABL that is transitional between the active and inactive conformations and is approximately 25-fold more potent than imatinib in vitro. 9 It should be noted that using in vitro data alone to assess drug sensitivity/potency fails to consider variables such as differences in levels of protein binding, cellular influx/efflux and pharmacokinetic factors. 16 Point mutations in the coding sequence of the ABL kinase domain of BCR-ABL are the best-characterized mechanism of imatinib resistance. Resistance has been associated with exchanges in 450 different amino acid residues within BCR-ABL. 17 In vitro, dasatinib and nilotinib are active against all imatinib-resistant BCR-ABL mutants tested except T315I. However, each agent has reduced potency toward specific mutants compared with unmutated BCR-ABL: F317L and E255V for dasatinib, and Y253F/H, E255K/V and F359V for nilotinib. 8 Bosutinib is less active against the V299L and E255K/V mutants and inactive against T315I. 10 In line with these in vitro data, clinical resistance to dasatinib is mainly associated with mutation of V299, T315 and F317, while nilotinib resistance is mainly associated with mutations of Y253, E255, T315 and F359. [18] [19] [20] [21] [22] [23] Clinical data relating to types of mutant are more limited for bosutinib, although minimal activity in patients with T315I was confirmed. 24 During in vitro mutagenesis studies, dasatinib or nilotinib treatment of cell lines expressing BCR-ABL led to fewer types of mutations occurring and a lower frequency of mutated clones overall compared with imatinib. 25, 26 Following clinical trials, both dasatinib and nilotinib were approved for treating patients with imatinib-resistant or imatinib-intolerant CML-CP or CML-AP. 27, 28 Dasatinib has also been approved for patients with CML-BP or Ph þ acute lymphoblastic leukemia after prior imatinib therapy.
Should second-generation BCR-ABL inhibitors be used for first-line therapy?
Historical data suggest that optimal outcomes are achieved when patients with CML receive first-line therapy with the most effective agent available. Initial clinical evaluations of imatinib took place in patients who had resistance or intolerance to prior IFN therapy. In a phase 2 single-arm international multicenter study of patients with CML-CP, second-line imatinib treatment resulted in an 18-month CCyR rate of 41%. 29 CCyR rates with first-line IFN/cytarabine in the IRIS trial at 18 months were only 9%, suggesting that with a treatment strategy of first-line IFN and second-line imatinib, roughly half of the patients would achieve CCyR overall. This compares with the 18-month CCyR rate of 76% in patients who received first-line imatinib in the IRIS trial. 30 Studies by the MD Anderson Cancer Center in Houston and the Italian GIMEMA working party on CML have also reported higher response rates with first-line imatinib compared with imatinib post IFN. 31, 32 It is important to note that many patients in these studies had received IFN for prolonged periods of time, and outcomes of patients treated with second-line imatinib (after IFN/cytarabine) in the IRIS study were almost as good as those for patients treated with imatinib upfront. 30 Nonetheless, all in all the data indicate that starting treatment with a more effective therapy is preferable to late intensification. From a biological perspective, this is expected because BCR-ABL activity has a critical role in disease progression by promoting genetic instability. [33] [34] [35] [36] [37] This implies that earlier inhibition of kinase activity should prevent progression events.
Treatment responses in patients with CML-CP are improved when BCR-ABL is inhibited more effectively. CML cells were isolated from participants in the Australian multicenter phase 2 TIDEL (Trial of Initial Intensified Imatinib Therapy and Sequential Dose-EscaLation) study of first-line imatinib, and levels of BCR-ABL inhibition were assessed by measuring phosphorylation of CrkL, a biomarker for BCR-ABL activity. Among patients who had a 450% reduction in phospho-CrkL during the first month of treatment, 100% obtained a MMR by 24 months compared with 56% of patients who failed to achieve 50% kinase inhibition (Po0.001). 38 Plasma concentrations of imatinib available to inhibit BCR-ABL vary between patients and several studies have found a correlation between the trough plasma levels of imatinib and response to treatment, including a study by Picard et al. 39 (n ¼ 68) and a subanalysis of the IRIS trial (n ¼ 351). 40 Prospective studies performed at the Hammersmith Hospital and by Belgian centers (ADAGIO; ADherence Assessment with Glivec: Indicators and Outcomes) have also shown that nonadherence to imatinib treatment is associated with poor response. 41, 42 Across multiple studies, 31-48% of CML-CP patients failed to achieve CCyR and 60-88% failed to achieve MMR by 12 months with first-line imatinib treatment. 1, 5, [43] [44] [45] [46] In patients with CML-CP receiving first-line imatinib, a delayed reduction of leukemia burden increases the risk of progression. In an analysis of IRIS data, patients who achieved a CCyR at 3, 6, 12 and 18 months showed a consistent trend for lower 8-year rates of events (loss of response or disease progression) compared with patients who achieved lesser cytogenetic responses at these time points. 4 In patients treated at the Hammersmith Hospital, those not in CCyR by 12 months had lower 5-year rates of transformation-free survival (TFS: 74% vs 96%; P ¼ 0.007) and overall survival (OS: 74% vs 98%; P ¼ 0.03) compared with patients who had achieved a CCyR by 12 months. 5 In the IRIS trial, achieving a MMR (BCR-ABL p0.1% using the international scale) by 12 months was associated with significantly higher 7-year rates of TFS compared with a BCR-ABL transcript level reduction to only 0.1-1%. 3 An earlier IRIS analysis found that no patient with both a CCyR and MMR at 12 months had transformed to AP/BP at 5 years, compared with 5% of patients with a CCyR but no MMR (P ¼ 0.007).
1,47 Although analyses Table 1 Comparison of the potency and selectivity of imatinib, dasatinib, nilotinib and bosutinib for BCR-ABL in vitro [8] [9] [10] [11] [12] [13] [14] Fold increase in potency against BCR-ABL in cellular proliferation assays relative to imatinib Comparative potency against BCR-ABL, PDGFRb, KIT and SRC based on IC 50 values in proliferation/kinase assays from IRIS and Hammersmith cohorts found no TFS advantage for patients who achieved CCyR and MMR at 18 months compared with patients who achieved CCyR alone, achieving a MMR by 12-18 months in both cohorts significantly reduced the probability of losing CCyR. 1, 3, 48 Thus, if faster responses and higher response rates can be achieved with alternative strategies, such as more potent BCR-ABL inhibitors, this may improve longer-term outcomes in patients with newly diagnosed CML-CP.
Developing a BCR-ABL mutation during imatinib treatment for CML-CP is associated with loss of response and disease progression. 49 First-line treatment with newer BCR-ABL inhibitors, which have broader mutational coverage than imatinib, may reduce the likelihood of a resistance mutation emerging and decrease the risk of disease progression. Whereas BCR-ABL mutations have a strong association with acquired resistance, 50 other mechanisms may be more relevant to patients with primary resistance/suboptimal response. The organic cation transporter (OCT-1) is an important mediator of active imatinib influx. In a study of patients recruited to the TIDEL and TOPS trials, the majority of patients who had a suboptimal response to imatinib had low (no more than median) levels of OCT-1 activity. 51 In addition, MMR rates by 60 months were higher in patients with high vs low OCT-1 activity (89% vs 55%, P ¼ 0.007), as were OS rates (96% vs 87%, P ¼ 0.028). 52 Unlike imatinib, the cellular uptake of dasatinib and nilotinib is not mediated by OCT-1, so the activity of OCT-1 is unlikely to affect response to these agents. 53, 54 Efflux proteins represent another potential resistance mechanism, although data are more limited compared with OCT-1. In a series of 33 patients, overexpression of ABCB1 (MDR1), belonging to the family of ATP-binding cassette transporters, was associated with failure to achieve a major cytogenetic response and transformation to advanced disease. 55 In vitro data indicate that dasatinib, like imatinib, is transported by the efflux proteins ABCB1 and ABCG2. 53, 56 Conflicting data have been reported for nilotinib. [57] [58] [59] [60] More work is needed to clarify the clinical significance of efflux proteins for BCR-ABL inhibitor resistance.
Results of second-generation BCR-ABL inhibitors in first-line treatment of CML-CP
Both nilotinib and dasatinib were initially assessed in the firstline setting in single-arm phase 2 studies. In a phase 2 study of 73 patients performed by the GIMEMA CML working party, firstline nilotinib 400 mg twice daily (BID) treatment resulted in CCyR and MMR rates in all enrolled patients of 78% and 52% at 3 months and 96% and 85% at 12 months, respectively. 61 In a study from the MD Anderson Cancer Center of nilotinib 400 mg BID in 61 patients with CML-CP followed for a median of 17 months, cumulative CCyR and MMR rates among 51 patients with X3 months of follow-up were 98% and 76%, respectively. Responses occurred rapidly, with 98% of 45 evaluable patients in CCyR at 6 months. Rates of event-free survival and OS in all 61 patients at 24 months were 90% and 100%, respectively. 62 Similar results were found in a study from the same institution of 62 patients with CML-CP treated with dasatinib 100 mg daily who were followed for a median of 24 months. Cumulative CCyR and MMR rates in 50 patients with X3 months of followup were 98% and 82%, respectively. Again, responses occurred rapidly, with 94% of 49 evaluable patients in CCyR at 6 months; 24-month event-free survival and OS rates in all 62 patients were 88% and 100%, respectively. 63 More recently, both nilotinib and dasatinib have shown superior efficacy over imatinib in randomized multinational phase 3 trials in patients with newly diagnosed CML-CP ( Table 2 ). The ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in Clinical TrialsFNewly Diagnosed Patients) randomized 846 patients stratified by Sokal risk score to receive nilotinib 300 or 400 mg BID or imatinib 400 mg once daily. 64 Both nilotinib arms showed superior efficacy compared with the imatinib arm, including higher rates of MMR at 12 months (primary endpoint; 44% vs 43% vs 22%; Po0.001 for both nilotinib arms vs imatinib) ( Table 2) . 65 The CCyR and MMR advantage for nilotinib over imatinib was also seen in patients with a high Sokal risk score. Rates of BCR-ABL transcript reductions to p0.0032% (4.5-log reduction from standardized baseline) by 24 months were also higher in the nilotinib 300 and nilotinib 400 arms compared with the imatinib arm (25%, 19% and 9%, respectively). 66 After a minimum follow-up of 24 months, transformation to AP/BP CML or death on study had occurred in 0.7% of patients receiving nilotinib 300 mg BID, 1.1% receiving nilotinib 400 mg BID and 4.2% receiving imatinib 400 mg QD. 66 Based on a Kaplan-Meier analysis of time to AP/BP, a significant advantage in TFS was seen for both nilotinib 300 mg BID (P ¼ 0.0059) and nilotinib 400 mg BID (P ¼ 0.0196) compared with imatinib. In a comparison of safety profiles at 24 months follow-up (Table 3) , grade 3/4 thrombocytopenia occurred at a similar frequency in all arms, whereas grade 3/4 neutropenia occurred more frequently in the imatinib arm. Different patterns of nonhematologic AEs of any grade were seen for nilotinib and imatinib, including fewer gastrointestinal (nausea, diarrhea and vomiting), muscle spasm and fluid retention (peripheral edema, eyelid edema and periorbital edema) AEs with nilotinib than with imatinib, whereas dermatologic AEs (rash, pruritus and alopecia) and headache were more common with nilotinib. 66 Pleural effusion occurred in 0-o1% in each arm. 67 Rates of grade 3/4 nonhematologic AEs were low in all arms. However, rates of several grade 3/4 biochemical abnormalities were higher with nilotinib compared with imatinib, including grade 3/4 elevations in alanine aminotransferase, bilirubin, lipase and glucose (Table 3) . 66 As a result of occurrences of QT prolongation and cardiac-related sudden death in previous nilotinib trials, patients were closely monitored for QT prolongation during the ENESTnd trial. At the 24-month data cut-off, one patient in the imatinib arm and no patient in the nilotinib arms had experienced a QT interval prolongation to 4500 ms. No patient in the ENESTnd study had a decrease in the mean ventricular ejection fraction to o45%.
In the DASISION trial (Dasatinib Versus Imatinib Study In Treatment-naïve CML), 519 patients stratified by Hasford risk score were randomly assigned to receive dasatinib 100 mg QD (n ¼ 259) or imatinib 400 mg QD (n ¼ 260). 68 Superior efficacy was seen in the dasatinib arm compared with the imatinib arm, including higher 12-month rates of confirmed CCyR (primary endpoint, defined as CCyR detected on two consecutive assessments; 77% vs 66%; P ¼ 0.0067) ( Table 2) . 68, 69 More than half of dasatinib-treated patients (54%) had achieved a CCyR at 3 months compared with 31% for imatinib. 68 By 24 months, more dasatinib-treated patients than imatinib-treated patients had achieved a BCR-ABL transcript level reduction to p0.0032% (17% vs 8%). Transformation to AP/BP CML on study occurred in 2.3% with dasatinib and 5.0% with imatinib. This difference did not reach statistical significance. 69 In a comparison of safety profiles (Table 3) , grade 3/4 neutropenia occurred with similar frequency, whereas grade 3/4 thrombocytopenia occurred in more patients receiving dasatinib than imatinib. Of nonhematologic treatment-related AEs that occurred at any grade in X10% of either arm, rates of several nonhematologic AEs were lower with dasatinib compared with imatinib, including overall fluid retention, superficial edema, nausea, vomiting, rash and myalgia. 69 Pleural effusion was only observed in the dasatinib arm, occurring in 14% (grade 1 in 3%, grade 2 in 10% and grade 3 in o1%), but pleural effusions did not negatively influence 24-month response rates (CCyR in 95% and MMR in 68% of patients who had a pleural effusion). 70 Rates of grade 3/4 nonhematologic AEs were low (0-1%) in both arms, and except for grade 3/4 hypophosphatemia (7% with dasatinib vs 25% with imatinib), rates of biochemical abnormalities were low. 69 Similar findings to the DASISION trial were reported in a randomized phase 2b intergroup trial of dasatinib vs imatinib performed in several US/Canadian centers ( Table 2) . 71 In previous studies of dasatinib in the second-line setting, persistent expansion of clonal cytotoxic T cells or NK cells in patients with CML or Ph þ acute lymphoblastic leukemia has been seen, and this lymphocytosis has been associated with improved responses and increased incidence of immune-related AEs. [72] [73] [74] [75] [76] In a post hoc analysis of the DASISION trial, lymphocytosis occurred more frequently in patients treated with dasatinib than with imatinib (24% vs 5%). Dasatinib-treated patients who developed lymphocytosis had a trend for an improved 12-month CCyR rate (84% vs 75%) and an increased rate of pleural effusion (any grade; 18% vs 8%) compared with those who did not develop lymphocytosis. The mechanism responsible for lymphocytosis in dasatinib-treated patients has not been determined, but it has been suggested that some antileukemic effects of dasatinib are produced by an immunomodulatory mechanism that may also contribute to the pleural effusions. 77 In the phase 3 multinational randomized BELA trial (Bosutinib Efficacy and safety in newly diagnosed chronic myeloid LeukemiA), patients with newly diagnosed CML-CP received bosutinib 500 mg QD (n ¼ 250) or imatinib 400 mg QD (n ¼ 252). Data were recently reported after a median treatment duration of 14 months. Although the trial failed to achieve its primary endpoint because of the lack of a difference in 12-month CCyR rate between the bosutinib and imatinib arms (70% vs 68%; P ¼ 0.601), bosutinib treatment was associated with a higher 12-month MMR rate compared with imatinib (39% vs 26%; P ¼ 0.002). Transformation to AP/BP by 12 months had occurred in 1.6% vs 4.0%, respectively (P ¼ 0.053). Safety data showed a lower rate of grade 3/4 neutropenia for bosutinib vs imatinib (8.9% vs 22.7%), whereas rates of anemia (6%) and thrombocytopenia (13%) were similar in both arms. For nonhematologic AEs of any grade, diarrhea (68% vs 21%), vomiting (32% vs 13%), pyrexia (16% vs 9%) and abdominal pain (12% vs 5%) arose more often with bosutinib compared with imatinib, whereas bone pain (4% vs 10%), muscle cramps (2% vs 20%) and periorbital edema (o1% vs 14%) occurred more frequently with imatinib. Notable grade 3/4 nonhematologic AEs for bosutinib vs imatinib were diarrhea (10% vs 1%) and vomiting (3% vs 0%); rates of other types of grade 3/4 AE were p1%. Rates of several biochemical abnormalities were higher for bosutinib compared with imatinib including elevated levels of alanine aminotransferase (21% vs 3%), AST (10% vs 3%) and lipase (7% vs 5%), whereas the rate of hypophosphatemia was lower for bosutinib (4% vs 14%). Five-year follow-up is planned. 78 Based on the results of the ENESTnd and DASISION trials, nilotinib 300 mg BID and dasatinib 100 mg QD are now approved for first-line treatment of CML-CP. A summary of response rates at 12 and 24 months from the key phase 3 clinical trials of imatinib, dasatinib, nilotinib and bosutinib can be found in Table 2 . 
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Second-generation BCR-ABL inhibitors in first-line CML therapy: a critical appraisal
Need for long-term follow-up
Phase 3 trials have shown that both dasatinib and nilotinib are associated with higher CCyR and MMR rates at early time points compared with imatinib treatment. However, longer follow-up is needed to show that the advantage in response rates is maintained over time. The difference in transformation to AP/BP CML on study has reached statistical significance in the ENESTnd trial and provides the first suggestion that long-term outcomes may be improved with the more potent inhibitors. Based on the predictive significance of early responses for decreasing the risk of disease progression, this difference may increase over time. However, because patients with CML-CP now have low mortality, long-term follow-up may be needed before any difference in OS is seen.
Discontinuations
Although results were positive in favor of dasatinib and nilotinib in recent trials, rates of drug discontinuation require closer examination. In the dasatinib and imatinib arms of the DASISION trial, 23% vs 25% of patients had discontinued therapy by 24 months. Reasons for discontinuation included disease progression or treatment failure (8.5% vs 10.9%), drugrelated or -unrelated AEs (8.9% vs 5.0%) and death in 1.6% vs 0.4%, respectively. 69 In the ENESTnd trial, 26% of the nilotinib 300 mg BID arm and 22% of the nilotinib 400 mg BID arm had discontinued therapy by 24 months compared with 33% of the imatinib arm. Reasons for discontinuation were suboptimal response or treatment failure in 1% vs 1% vs 2%, transformation to AP/BP CML in o1% vs 1% vs 4%, AEs or laboratory abnormalities in 9% vs 13% vs 10% and death in 1% vs o1% vs 0%, respectively. In addition, 7% vs o1% vs 11% discontinued following suboptimal response/treatment failure and entered an extension study. 66 In the bosutinib and imatinib treatment arms of the BELA trial, 29% vs 20% had discontinued treatment by 12 months, respectively. More patients discontinued bosutinib than imatinib as a result of AEs (19% vs 5%), whereas discontinuation because of treatment failure or disease progression occurred in 3 and 10%. 78 Although discontinuation rates in each of these phase 3 trials are not excessively high, full interpretation of data will require long-term outcomes to be considered both in Table 3 Rates of treatment-related AEs (X10%), hematologic AEs and biochemical abnormalities in patients treated with imatinib, dasatinib or nilotinib in the DASISION and ENESTnd trials (24-month follow-up) 66 Second-generation BCR-ABL inhibitors as first-line therapy PJ Shami and M Deininger patients who remained on study and in those who discontinued prematurely (that is, intention-to-treat analysis).
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Choice of follow-up therapy
One factor to consider with respect to the choice of newer agents for first-line therapy is the lack of an established salvage agent in that setting. Third-line nilotinib treatment induced responses in a study of patients who had prior resistance to both imatinib and dasatinib, 81 suggesting that nilotinib may be an option following first-line dasatinib. Similarly, dasatinib treatment resulted in responses in patients with both imatinib and nilotinib failure. 82 There have also been occasional reports of patients who have developed a mutation during therapy with dasatinib or nilotinib and have subsequently responded to treatment with the other agent, in line with the different spectra of mutations associated with clinical resistance to each agent. 83, 84 A range of novel agents are in development that may in the future provide additional options for salvage therapy. Examples include agents that have inhibitory activity against the T315I-mutated form of BCR-ABL, such as aurora/ BCR-ABL kinase inhibitors (XL228, PHA-739358/danusertib, and AT9283), [85] [86] [87] [88] [89] multitargeted kinase inhibitors (AP24534/ ponatinib) [90] [91] [92] and switch pocket kinase inhibitors (DCC-2036 and DCC-2157). 93, 94 Allogeneic stem-cell transplant also remains an acceptable salvage option for CP patients with an available donor. In patients who have transformed to AP/BP, allotransplant remains the salvage therapy of choice. It is important to note that with more effective first-line therapy, it is expected that fewer patients will require salvage and as such, the concern for losing dasatinib and nilotinib as a salvage option is not justified based on currently available data.
Modified imatinib-based treatment
In addition to trials of newer BCR-ABL inhibitors, higher doses than standard imatinib therapy have been explored. In the international phase 3 TOPS trial of standard imatinib 400 mg/ day (n ¼ 157) vs a higher 800 mg/day dose (n ¼ 319) in patients with newly diagnosed CML-CP, MMR and CCyR rates were higher at 3 and 6 months in the 800 mg/day arm, but no difference was seen at 12 months for MMR (primary endpoint) or CCyR ( Table 2) . 43 Furthermore, no difference in event-free survival, TFS or OS was seen at 24 months. 95 Imatinib 800 mg/ day was associated with a higher occurrence of AEs and discontinuations compared with imatinib 400 mg/day. 43 In a randomized phase 2 study performed by the European LeukemiaNet in patients with CML-CP and high Sokal risk scores (n ¼ 216), response rates at 12 months or earlier were similar in patients assigned to imatinib 400 or 800 mg/day. 96 A large randomized phase 3 trial (CML IV) of imatinib 800 mg/day vs imatinib 400 mg/day vs imatinib 400 mg plus IFN is being performed by the German CML Study Group. A key distinction of the trial is that patients in the 800 mg/day arm received imatinib 400 mg/day for the first 6 weeks before undergoing escalation to 800 mg/day, and subsequent doses were adapted according to AEs to improve tolerability. Cumulative response rates by 12 months were higher for imatinib 800 vs 400 and 400 mg/day plus IFN arms, including CCyR MMR, and BCR-ABL p0.01% (Table 2) . 46 In the French phase 3 SPIRIT trial, 636 patients were randomized to receive imatinib 400 mg/day alone, or 600 mg/day alone, 400 mg/day plus cytarabine or 400 mg/day plus pegylated IFN. Although no significant difference was seen in 12-month rates of CCyR, imatinib 400 mg/day plus pegylated IFN was associated with higher rates of MMR and BCR-ABL p0.01% compared with the other arms ( Table 2) . Adding pegylated IFN to imatinib resulted in an increased incidence of AEs, particularly grade 3/4 neutropenia and thrombocytopenia. 45 In both the German and French studies, no significant difference has been reported to date in rates of long-term TFS or OS between trial arms. Based on these results, it is hard to justify the use of high-dose imatinib in the first-line setting and a consensus is yet to be reached on first-line use of imatinib plus IFN. There are no data comparing the latter approach with newer BCR-ABL inhibitors in the first-line setting.
Future directions of CML treatment

Improving prognostication
With the existing scoring systems (Sokal and Hasford), superiority of dasatinib and nilotinib over imatinib was observed across the risk spectrum, but response rates were still lower in high-risk patients. On the other hand, rates of transformation to AP/BP were very low in good-risk patients, both in the DASISION and ENESTnd trial, suggesting that the strongest case to use the latter drugs upfront can be made for patients in the higher risk categories. Regardless, it is clear that some negative biologic factors are not entirely overcome with more potent agents. There is therefore a need to develop additional prognostic parameters in order to better understand the biology of high-risk disease. One promising technique for identifying novel prognostic characteristics is microarray-based gene expression profiling. In a recent study to identify biomarkers predictive of imatinib failure, gene expression profiling of CD34-positive cells from two independent cohorts of imatinibnaive patients with CML-CP identified 885 probe sets with differential expression between responders and nonresponders (based on 12-month major cytogenetic response). From this, a 75-probe classifier set was identified that was predictive for 88% of responders and 83% of nonresponders, and was found to overlap with signatures for transformation to AP/BP, particularly genes regulated by b-catenin. These observations suggest that CML-CP patients destined to fail on imatinib may be identified by characteristics other than clinical criteria. The investigators suggested that the classifier gene set could be used to identify patients who would be most likely to benefit from more intensive/potent upfront therapy. 97 Conversely, once generic imatinib is available, this prognostication tool could be used to identify patients likely to do well with the less expensive generic drug. Comparative genomic hybridization is also being investigated as a potential molecular prognostication tool in patients with CML. Studies to date have identified DNA copy number changes that are more frequent in patients with advanced disease, suggesting that this technique could also identify molecular characteristics predictive of poor or good responses to treatment.
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Can imatinib be discontinued in some patients?
In the French multicenter STop IMatinib (STIM) study, patients with a sustained complete molecular response (defined as a 45-log reduction in BCR-ABL/ABL level, that is, undetectable signal on quantitative reverse transcriptase-PCR, lasting 42 years) who had received at least 3 years of imatinib therapy, discontinued drug. Of 69 evaluable patients, the probability of persistent complete molecular response at 12 months after stopping imatinib was 41% (95% CI 29-52). Within available follow-up, 42 (61%) patients had a molecular recurrence; 40 before 6 months, 1 patient at 7 months and 1 patient at 19 months. All patients who relapsed responded to reintroduction of imatinib, including 26 who achieved sustained complete molecular response. 101 These data suggest that in a proportion of patients, molecular remission achieved on imatinib may be maintained in the absence of treatment, although longer-term follow-up is needed. A confirmatory study with a larger number of patients would also be helpful. It is unknown at this stage whether the leukemic clone has been eliminated in patients who maintain molecular remission. Emerging data suggest this may not be the case, as a study of 18 patients enrolled in the ongoing Australasian Leukaemia and Lymphoma Group CML8 study found that among eight patients who maintained molecular remission for 12-41 months after discontinuing imatinib, seven remained positive for BCR-ABL using DNA-based assays. 102 Additionally, it is technically impossible to prove that all CML cells have been eliminated. Based on current data, BCR-ABL inhibitor therapy should only be discontinued within the context of a clinical trial.
Beyond BCR-ABL tyrosine kinase inhibitors
Increasing evidence indicates that quiescent CML stem cells and early progenitors are largely resistant to BCR-ABL inhibitors, despite inhibition of BCR-ABL kinase activity. [103] [104] [105] [106] Thus, eliminating these cells will require alternative approaches, such as drug combinations or immunotherapeutic approaches. One possibility may be combination therapy between a BCR-ABL inhibitor and an agent that targets a pathway that is critical to stem cell survival, such as inhibitors of Hedgehog signaling pathway, b-catenin, promyelocytic leukemia protein, Forkhead box class O transcription factors and Alox5 (gene for arachidonate 5-lipoxygenase). [107] [108] [109] [110] [111] Less-specific agents with in vitro activity include farnesyl transferase inhibitors, histone deacetylase inhibitors and omacetaxine. [112] [113] [114] Perhaps the most promising candidate for combination therapy at this point is IFN, which activates dormant hematopoietic stem cells in vivo. 115 Although combining IFN with imatinib has not yet been found to improve OS, the higher rates of MMR and complete molecular response suggest that this is a promising strategy. However, one has to take into account the added toxicity associated with IFN therapy.
Conclusions
Although the majority of patients newly diagnosed with CML-CP respond to imatinib treatment, approximately one-third of patients experience imatinib resistance or intolerance. These patients may benefit from an alternative more effective treatment upfront. Patients who have delayed responses to imatinib are at increased risk of disease progression. As BCR-ABL is the driving force behind CML disease progression, more effective BCR-ABL inhibition may decrease the risk of disease progression. Recent studies have demonstrated that first-line treatment with dasatinib or nilotinib results in higher rates of CCyR and MMR by 12-24 months compared with imatinib, in addition to a lower rate of disease progression.
In practical terms, based on the current body of evidence, it is reasonable to use dasatinib or nilotinib in the treatment of newly diagnosed patients with CML-CP. As there are no data comparing both agents, one agent cannot be recommended over the other. The choice between the two treatments will have to be individualized based on the patient's other health conditions, drug interactions and compliance issues (once daily dosage vs twice daily dosage on an empty stomach). Imatinib remains an excellent choice for patients who would not be good candidates for nilotinib or dasatinib (for example, patients with a QTc interval at baseline close to 500 ms). Health-economic considerations are likely to have a major impact on practice patterns once generic imatinib becomes available in 2015. Long-term follow-up is required to determine how sustained the efficacy and tolerability advantage of the newer agents will be compared with imatinib with its excellent long-term safety record.
Conflict of interest
M Deininger is a paid consultant for Novartis, Bristol-Myers Squibb and ARIAD. PJ Shami has participated in Advisory Boards and Speaker Bureau for Novartis.
